Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
AstraZeneca
Queensland Health
Teva
Medtronic
Fuji
Farmers Insurance
US Army
Boehringer Ingelheim
US Department of Justice

Generated: August 24, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 8,778,324 protect, and when does it expire?


Patent ► Subscribe protects VELTASSA and is included in one NDA.

This patent has eighty-two patent family members in sixteen countries.

Summary for Patent: ► Subscribe

Title:Ion binding polymers and uses thereof
Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.
Inventor(s): Charmot; Dominique (Campbell, CA), Chang; Han-Ting (Livermore, CA), Liu; Mingjun (Campbell, CA), Klaerner; Gerrit (Los Gatos, CA)
Assignee: Relypsa, Inc. (Redwood City, CA)
Application Number:13/647,690
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-001Oct 21, 2015RXYesNo► Subscribe► Subscribe TREATMENT OF HYPERKALEMIA
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-002Oct 21, 2015RXYesNo► Subscribe► Subscribe TREATMENT OF HYPERKALEMIA
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-003Oct 21, 2015RXYesYes► Subscribe► Subscribe TREATMENT OF HYPERKALEMIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,287,847Ion binding polymers and uses thereof► Subscribe
8,889,115Ion binding polymers and uses thereof► Subscribe
8,216,560Ion binding polymers and uses thereof► Subscribe
8,282,913Ion binding polymers and uses thereof► Subscribe
7,429,394Ion binding compositions► Subscribe
8,282,960Ion binding compositions► Subscribe
7,854,924Methods and compositions for treatment of ion imbalances► Subscribe
8,409,561Methods and compositions for treatment of ion imbalances► Subscribe
7,556,799Ion binding polymers and uses thereof► Subscribe
8,475,780Ion binding polymers and uses thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan2013056909► Subscribe
BrazilPI0509331► Subscribe
BrazilPI0509365► Subscribe
BrazilPI0509366► Subscribe
Canada2557848► Subscribe
Canada2557999► Subscribe
Canada2558029► Subscribe
Canada2806465► Subscribe
Canada2829943► Subscribe
China1980639► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Chubb
Express Scripts
Moodys
Chinese Patent Office
US Department of Justice
Federal Trade Commission
Citi
Teva
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot